Dr. Veerappa Annasaheb Kothiwale is well-experienced senior consultant General Physician associated with K.L.E.S Heart Hospital and Dr. V.A.Kothiwale Clinic, Belgaum. He is the professor and the head of the medicine at the JN Medical College. After completing his MBBS and MD, Dr. Kothiwale went to USSR to complete Ph.D in Cardiology. He has taken a fellowship in respiratory and critical care medicine at Illinois university, Chicago.
Dr. Veerappa is deeply entrenched in research, had done several clinical trials and has mentored & guided medical students. Dr. Kothiwale has been recognized with Best teacher award for years 2009, 2010 and 2012. He has taken Best Clinician award for 2011. He has made several publications in national journals and his research work included various protocols.
MBBS, 1982, JN Medical College, Belgaum, India
MD (Medicine), 1986, JN Medical College, Belgaum, India
Ph.D (Cardiology), 1991, Strazesko Cardiac Research Centre, Kiev, Ukraine
Bhagavant Saka Complex,
Belgaum College Road, Belgaum, Karnataka - 590001
SUN, MON, TUE, WED, THU, FRI, SAT
12:30 PM - 02:30 PM
Your participation in the survey will help other patients make informed decisions. You will also be helping Dr.V.A. Kothiwale and his staff know how they are doing and how they can improve their services.
How was your experience with Dr.V.A. Kothiwale?
Help other patients, and let the doctor know how he's doing
rotocol Title: To study the safety and efficacy of R-TPR –001 (Reteplase- Recombinant plasminogen activator) in patients with acute myocardial infarction and ST segment elevation. Reliance - Approved by EC on 05/01/2011 – Completed
Protocol Title: To study the safety and efficacy of ReliDerm®DT in patients with chronic diabetic foot ulcer. Reliance - Approved by EC on 03/06/2009 – Completed
Protocol Number: DU176b-C-U301: A Phase 3, randomised, double-blind, double dummy, parallel group, multi-centre, multi-national study for evaluation of efficacy and safety of DU-176b Versus Warfarin In subjects with atrial fibrillation- effective aNticoaGulation with Factor xA next generation in atrial fibrillation (ENGAGE– AF TIMI – 48). Quintile - Company Approved by EC on 20/01/2010 - Status: Active - Screened 15, Randomised 10
Cardiovascular and respiratory responses to Valsalva maneuver, isometric handgrip exercise and Harvard Step test and recovery in healthy individuals. [Guide to Dr. Sanjvi Kumar (Department of Physiotherapy)]
Predictive criteria to select patients for Physiotherapy and rehabilitation, in patients with Neuropathy / Neurological deficits following acute ischemic episode of the limbs. [Guide to Dr. Ganesh B.R. (Department of Physiotherapy)]
Protocol Title: F1K-MC-EVDP, Efficacy and safety of Drotrecogin Alfa [activated] in adult patients with septic shock. Parexell - Approved by EC on 23/07/2009 but not initiated. Study close out